Kumar Srinivasan

A Director of Pulmotect, Kumar Srinivasan joined AstraZeneca in April 2012 and as of August 2019, Kumar assumed a new role as Vice President and Global Head of Business Development and Licensing, BioPharmaceuticals R&D, AstraZeneca. In his most recent external position, Kumar was Chief Business Officer at Probiodrug AG, then a private venture-funded German company developing novel treatments for Alzheimer’s disease and inflammatory diseases. Prior to joining Probiodrug, Kumar was Vice President, Global Business Development at Wyeth Pharmaceuticals, where he headed up business development and licensing activities for pre phase 2 opportunities for several therapeutic areas. Kumar has a Ph.D from Case Western University in chemistry, did his postdoctoral work at Caltech and has an MBA from the University of Chicago’s Booth School of Business.